MA30402B1 - Acides carboxyliques substitues par des phenylamino-benzoxazoles, leur procede de production et leur utilisation comme medicaments - Google Patents

Acides carboxyliques substitues par des phenylamino-benzoxazoles, leur procede de production et leur utilisation comme medicaments

Info

Publication number
MA30402B1
MA30402B1 MA31362A MA31362A MA30402B1 MA 30402 B1 MA30402 B1 MA 30402B1 MA 31362 A MA31362 A MA 31362A MA 31362 A MA31362 A MA 31362A MA 30402 B1 MA30402 B1 MA 30402B1
Authority
MA
Morocco
Prior art keywords
phenylamino
carboxylic acids
medicaments
production
substituted carboxylic
Prior art date
Application number
MA31362A
Other languages
English (en)
Inventor
Elisabeth Defossa
Markus Follmann
Thomas Klabunde
Viktoria Drosou
Gerhard Hessler
Siegfried Stengelin
Guido Haschke
Andreas Herling
Stefan Bartoschek
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA30402B1 publication Critical patent/MA30402B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE DES ACIDES CARBOXYLIQUES SUBSTITUÉS PAR DES PHÉNYLAMINO-BENZOXAZOLES ET LEURS SELS PHYSIOLOGIQUEMENT COMPATIBLES. L'INVENTION CONCERNE ÉGALEMENT LES COMPOSÉS DE FORMULE (I), DANS LAQUELLE R1, R2, R6, R7, R8, R9, R10, M ET X SONT DÉFINIS COMME DANS LA DESCRIPTION, ET LEURS SELS PHYSIOLOGIQUEMENT COMPATIBLES. LESDITS COMPOSÉS CONVIENNENT, PAR EXEMPLE, AU TRAITEMENT DU DIABÈTE.
MA31362A 2006-05-11 2008-11-05 Acides carboxyliques substitues par des phenylamino-benzoxazoles, leur procede de production et leur utilisation comme medicaments MA30402B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006021878A DE102006021878A1 (de) 2006-05-11 2006-05-11 Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
MA30402B1 true MA30402B1 (fr) 2009-05-04

Family

ID=38371048

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31362A MA30402B1 (fr) 2006-05-11 2008-11-05 Acides carboxyliques substitues par des phenylamino-benzoxazoles, leur procede de production et leur utilisation comme medicaments

Country Status (30)

Country Link
US (2) US20090149519A1 (fr)
EP (1) EP2024347B1 (fr)
JP (1) JP2009536629A (fr)
KR (1) KR20090006846A (fr)
CN (1) CN101437805B (fr)
AR (1) AR060990A1 (fr)
AU (1) AU2007250213B2 (fr)
BR (1) BRPI0711448A2 (fr)
CA (1) CA2651660A1 (fr)
CO (1) CO6241107A2 (fr)
CY (1) CY1113177T1 (fr)
DE (1) DE102006021878A1 (fr)
DK (1) DK2024347T3 (fr)
ES (1) ES2391203T3 (fr)
HR (1) HRP20120829T1 (fr)
IL (1) IL195179A0 (fr)
MA (1) MA30402B1 (fr)
MX (1) MX2008014102A (fr)
MY (1) MY148258A (fr)
NO (1) NO20085068L (fr)
NZ (1) NZ572692A (fr)
PL (1) PL2024347T3 (fr)
PT (1) PT2024347E (fr)
RS (1) RS52450B (fr)
RU (1) RU2434003C2 (fr)
SI (1) SI2024347T1 (fr)
TW (1) TW200812987A (fr)
UY (1) UY30338A1 (fr)
WO (1) WO2007131622A1 (fr)
ZA (1) ZA200808490B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
EP2061760A1 (fr) 2006-09-07 2009-05-27 Amgen, Inc Composés benzo-fusionnés destinés à être utilisés dans le traitement de troubles métaboliques
CA2662305C (fr) 2006-09-07 2012-04-17 Amgen Inc. Modulateurs heterocycliques du recepteur couple a la proteine g (gpr40)
ES2446419T3 (es) 2007-04-16 2014-03-07 Amgen, Inc Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
JP5591706B2 (ja) 2007-10-10 2014-09-17 アムジエン・インコーポレーテツド 置換ビフェニルｇｐｒ４０調節因子
US8716283B2 (en) 2007-11-07 2014-05-06 University Of Massachusetts Type III secretion inhibitors, analogs and uses thereof
WO2009111056A1 (fr) 2008-03-06 2009-09-11 Amgen Inc. Dérivés d'acide carboxylique conformationnellement dépendants, utiles dans le traitement de troubles du métabolisme
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
CA2798330A1 (fr) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones utilises en tant qu'inhibiteurs d'acide gras synthase (fasn)
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN103298469A (zh) 2010-08-31 2013-09-11 首尔大学校产学协力财团 PPARδ激动剂的胎儿重编程的用途
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
TW201317229A (zh) * 2011-09-14 2013-05-01 Daiichi Sankyo Co Ltd 稠合雜環衍生物
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
WO2015084692A1 (fr) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Composés bicycliques antidiabétiques
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
EP3273981B1 (fr) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Procédé et composition pharmaceutique pour une utilisation dans le traitement du diabète
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
WO2019160882A1 (fr) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Inhibiteurs pd -1/pd-l1
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CA3126021A1 (fr) 2019-01-11 2020-07-16 Naegis Pharmaceuticals Inc. Inhibiteurs de la synthese des leucotrienes
KR102375097B1 (ko) * 2021-04-01 2022-03-17 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1491863A (en) * 1973-10-23 1977-11-16 Lilly Industries Ltd 2,5-or 2,6-disubstituted benzoxazoles
US4025637A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5296486A (en) * 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
AU675680B2 (en) * 1992-10-14 1997-02-13 Merck & Co., Inc. Fibrinogen receptor antagonists
ATE244717T1 (de) * 1997-03-14 2003-07-15 Vertex Pharma Inhibitoren des impdh-enzyms
WO2000005223A2 (fr) * 1998-07-23 2000-02-03 Astrazeneca Ab Composes chimiques
WO2000049005A1 (fr) * 1999-02-16 2000-08-24 Aventis Pharma Limited Composes bicycliques et leur utilisation comme ligands du recepteur de l'integrine
GB0001346D0 (en) * 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
CA2427750C (fr) * 2000-11-04 2011-01-04 Aventis Pharma Limited Acides alcanoiqies substitues
CA2430978C (fr) * 2000-12-28 2012-05-15 Daiichi Pharmaceutical Co., Ltd. Inhibiteurs de vla-4
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
JP2006056830A (ja) * 2004-08-20 2006-03-02 Dai Ichi Seiyaku Co Ltd ２−アリールアミノベンゾオキサゾール誘導体

Also Published As

Publication number Publication date
SI2024347T1 (sl) 2012-11-30
BRPI0711448A2 (pt) 2011-11-08
EP2024347B1 (fr) 2012-08-01
RU2008148838A (ru) 2010-06-20
CO6241107A2 (es) 2011-01-20
DK2024347T3 (da) 2012-10-29
US8748465B2 (en) 2014-06-10
DE102006021878A1 (de) 2007-11-15
MY148258A (en) 2013-03-29
TW200812987A (en) 2008-03-16
IL195179A0 (en) 2009-08-03
PL2024347T3 (pl) 2013-01-31
HK1131978A1 (en) 2010-02-12
AR060990A1 (es) 2008-07-30
ES2391203T3 (es) 2012-11-22
MX2008014102A (es) 2008-11-14
NO20085068L (no) 2009-02-04
NZ572692A (en) 2011-03-31
PT2024347E (pt) 2012-10-09
CY1113177T1 (el) 2016-04-13
EP2024347A1 (fr) 2009-02-18
RS52450B (sr) 2013-02-28
US20090149519A1 (en) 2009-06-11
JP2009536629A (ja) 2009-10-15
KR20090006846A (ko) 2009-01-15
WO2007131622A1 (fr) 2007-11-22
AU2007250213B2 (en) 2013-04-11
ZA200808490B (en) 2009-10-28
CN101437805B (zh) 2012-05-30
RU2434003C2 (ru) 2011-11-20
HRP20120829T1 (hr) 2012-11-30
CN101437805A (zh) 2009-05-20
UY30338A1 (es) 2008-01-02
US20130303578A1 (en) 2013-11-14
CA2651660A1 (fr) 2007-11-22
AU2007250213A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
MA32598B1 (fr) Nouveaux benzamides, leur preparation et leur utilisation comme medicaments
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MY148258A (en) Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments
MA31979B1 (fr) (cyclopropylphenyl) phenyloxamides, leur procede de production et leur utilisation comme medicament
MA32787B1 (fr) Peptides antiviraux therapeutiques
MX2008014101A (es) Acidos carboxilicos sustituidos con 4,5-difenil-pirimidinilamino, metodo para su produccion y su uso como medicamentos.
EA201001585A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
MA31841B1 (fr) Modulateurs du gpr40 à biphényle substitué
MA31894B1 (fr) Composes organiques
MA30609B1 (fr) Imidazolidine-2,4-diones arylaminoaryl-alkyl-substituees, leur procede de synthese, les medicaments comprenant ces composes, et leurs applications.
EA201001733A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
TNSN07148A1 (en) (biphenyl) carboxylic acids and derivatives thereof
TN2010000175A1 (fr) Piperidino-dihydrothienopyrimidines substituees
JO2282B1 (en) Oxazole derivatives
BRPI0417543A (pt) quinolinas úteis no tratamento de doença cardiovascular
GEP20125565B (en) Lactam compounds and their pharmaceutical use
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
SE0403006D0 (sv) New compounds
EA200802329A1 (ru) Производные триазола ii
WO2008010238A3 (fr) Nouveaux composés antidiabétiques
EA200802054A1 (ru) Ингибиторы фермента
MA29604B1 (fr) Complexe actif stable de sels de l'acide o-acetylsalicylique contenant des acides amines basiques et de la glycine
MA38315B1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales